Calling consciousness an "entropic engine" points to something psychologically obvious: selfhood costs energy. Maintaining a stable "me" model across time, contexts, and internal contradictions ...
C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...
The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback